All patients were Caucasian. KIR-ligand mismatch is reported in the NK cell donor versus patient vector. Patient 012 was reenrolled at a higher dose level as patient 019. UPN, universal patient number; WHO, World Health Organization; DLT, dose-limiting toxicity; M, male; F, female; IWG, International Working Group; TF-PD, treatment failure due to progressive disease; CR, complete remission; MLFS, morphologic leukemia-free state; CRi, CR with incomplete blood count recovery; MDS, myelodysplastic syndrome.
UPN | Dose level | Gender | Age (years) | WHO diagnosis | Number of previous therapies | Pretreatment BM blast (%) | KIR-ligand mismatch | IWG response | DLT | GVHD |
001 | 1 | M | 73 | M2 | 2 | 16 | Yes | TF-PD | No | No |
006 | 1 | M | 70 | M0 | 3 | 28 | Yes | TF-PD | No | No |
007 | 1 | M | 77 | M0 | 1 | 47 | Yes | CR | No | No |
008 | 2 | M | 76 | t-AML | 3 | 17 | Yes | TF-PD | No | No |
009 | 2 | F | 73 | M1 | 3 | 80 | No | MLFS | No | No |
012 | 2 | F | 71 | M5 | 3 | 15 | Yes | CR | No | No |
017 | 3 | M | 64 | t-AML | 3 | 69 | Yes | TF-PD | No | No |
019 | 3 | F | 71 | M5 | 4 | 15 | Yes | CR | No | No |
020 | 3 | M | 60 | MDS-AML | 1 | 13 | Yes | CRi | No | No |